Evolent Health, Inc. (EVH) Stock Forecast
EVH analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.29 / 5 from 14 analysts
- Price target
- $5.75 average of analyst targets
- Upside to target
- +25.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.05
- 52-week range
- $2.17 – $8.18
EVH analyst ratings
14 analystsNumber of analysts at each rating.
EVH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EVH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.06 | $0.01 | $0.09 | $0.05 | +20.0% | 9 |
| Current fiscal year (2026) | $0.20 | $0.10 | $0.27 | $0.09 | +122.1% | 9 |
| Next fiscal year (2027) | $0.40 | $0.28 | $0.52 | $0.20 | +102.0% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EVH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $727.1M | $686.9M | $754.7M | +51.6% | 14 |
| Current fiscal year (2026) | $2.64B | $2.56B | $2.67B | +40.5% | 14 |
| Next fiscal year (2027) | $3.30B | $3.14B | $3.46B | +25.1% | 14 |
EVH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EVH revenue: reported and forecast
EVH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.05 | $0.04 | $0.06 | $0.06 | $0.06 | +12.1% | 5 up · 3 down |
| Current fiscal year (2026) | $0.20 | $0.19 | $0.20 | $0.20 | $0.20 | +1.7% | 8 up · 1 down |
| Next fiscal year (2027) | $0.38 | $0.34 | $0.39 | $0.40 | $0.40 | +4.9% | 5 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EVH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EVH beat in 5 of 12.
What analysts expect from EVH
14 analysts cover Evolent Health; their consensus rating is buy (4.29 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.75, 25.8% above the latest close of $4.57. Analysts expect earnings of $0.20 per share for 2026, +122.1% from a year earlier. For 2027 the average estimate is $0.40 per share on revenue of $3.3 billion. Evolent Health beat the EPS estimate in 5 of the last 12 quarters.
Related: EVH income statement, EVH key metrics, EVH chart. See the EVH stock overview for the latest quote and news.
EVH forecast FAQ
What is Evolent Health's price target?
The average analyst price target for Evolent Health is $5.75, 25.8% above the latest close of $4.57.
Is Evolent Health a buy, hold or sell?
Of 14 analysts covering Evolent Health, 7 rate it a strong buy, 4 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Evolent Health's EPS forecast?
Analysts forecast $0.20 per share for 2026 (range $0.10 to $0.27); for 2027 the estimate is $0.40.
What is Evolent Health's revenue forecast?
The average revenue estimate for 2026 is $2.6 billion, growth of 40.5%; for 2027 it is $3.3 billion.
When does Evolent Health report earnings?
Evolent Health is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.05.
Does Evolent Health usually beat earnings estimates?
Evolent Health reported EPS at or above the analyst estimate in 5 of the last 12 quarters.